The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.
[More]
Bone Medical Ltd, a biopharmaceutical company focused on the development of new medicines for musculoskeletal diseases, today announced initial findings from a proof of concept study of BN006, a treatment that it is developing for Rheumatoid Arthritis (RA) based on its Mozaic™ peptide discovery technology.
[More]
The U.S. Food and Drug Administration today approved Cometriq (cabozantinib) to treat medullary thyroid cancer that has spread to other parts of the body (metastasized).
[More]
Serum procalcitonin measurements could improve the accuracy of pneumonia diagnoses when chest radiographs give indeterminate results, indicate US study findings.
[More]
Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.
[More]
Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).
[More]
Unigene Laboratories, Inc., today announced financial results for the first quarter ended March 31, 2012.
[More]
Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.
[More]
Unigene Laboratories, Inc., today announced financial results for the fourth quarter and full-year ended December 31, 2011.
[More]
Unigene Laboratories, Inc., a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that it had been granted U.S. Patent No. 8,076,291 from the United States Patent and Trademark Office.
[More]
Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.
[More]
Tarsa Therapeutics today presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA-, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.
[More]
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced second quarter financial results for the period ended June 30, 2011. The Company highlighted significant progress achieved in the second quarter with the continued execution of its turnaround strategy.
[More]
Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.
[More]
Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.
[More]
A new study may explain why only 50% of patients experiencing chronic nerve pain achieve even partial relief from existing therapeutics. The study, published in the June 6 online version of the international research journal PAIN, reveals that certain types of chronic pain may be caused by signals from the skin itself, rather than damage to nerves within the skin, as previously thought.
[More]
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.
[More]
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.
[More]
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.
[More]
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.
[More]